Kestra Medical Technologies (NASDAQ:KMTS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Kestra Medical Technologies (NASDAQ:KMTS) from a hold rating to a sell rating in a report issued on Sunday.

Separately, Wells Fargo & Company cut their price objective on shares of Kestra Medical Technologies from $28.00 to $27.00 and set an “overweight” rating for the company in a research report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $27.33.

Kestra Medical Technologies Stock Performance

Kestra Medical Technologies stock opened at $24.33 on Friday. The stock has a 50-day simple moving average of $18.23 and a 200 day simple moving average of $20.12. The company has a current ratio of 6.84, a quick ratio of 6.84 and a debt-to-equity ratio of 0.23. Kestra Medical Technologies has a 52 week low of $13.25 and a 52 week high of $27.71.

Institutional Investors Weigh In On Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in KMTS. Brown Advisory Inc. acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at approximately $13,716,000. Caas Capital Management LP acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at approximately $1,470,000. Jennison Associates LLC acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at approximately $1,869,000. TD Asset Management Inc acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at approximately $2,306,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at approximately $9,968,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.